home / stock / algs / algs quote
Last: | $0.52 |
---|---|
Change Percent: | 0.0% |
Open: | $0.53 |
Close: | $0.52 |
High: | $0.53 |
Low: | $0.51 |
Volume: | 81,349 |
Last Trade Date Time: | 07/30/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.52 | $0.53 | $0.52 | $0.53 | $0.51 | 81,349 | 07-30-2024 |
$0.53 | $0.5302 | $0.53 | $0.5398 | $0.52 | 36,358 | 07-29-2024 |
$0.5399 | $0.5398 | $0.5399 | $0.550099 | $0.5147 | 55,068 | 07-26-2024 |
$0.54 | $0.5203 | $0.54 | $0.5482 | $0.4966 | 436,785 | 07-25-2024 |
$0.539 | $0.547 | $0.539 | $0.547 | $0.5103 | 88,495 | 07-24-2024 |
$0.55 | $0.56 | $0.55 | $0.561 | $0.5298 | 201,352 | 07-23-2024 |
$0.5595 | $0.515 | $0.5595 | $0.5671 | $0.501 | 404,295 | 07-22-2024 |
$0.5037 | $0.49 | $0.5037 | $0.519 | $0.485 | 147,198 | 07-19-2024 |
$0.493 | $0.51 | $0.493 | $0.523 | $0.4823 | 540,111 | 07-18-2024 |
$0.5153 | $0.5225 | $0.5153 | $0.53 | $0.5 | 239,706 | 07-17-2024 |
$0.5258 | $0.5062 | $0.5258 | $0.542 | $0.4945 | 291,435 | 07-16-2024 |
$0.5099 | $0.5043 | $0.5099 | $0.5299 | $0.4859 | 166,997 | 07-15-2024 |
$0.5199 | $0.52 | $0.5199 | $0.5377 | $0.5061 | 310,424 | 07-12-2024 |
$0.5114 | $0.51 | $0.5114 | $0.558 | $0.5045 | 785,031 | 07-11-2024 |
$0.5098 | $0.4962 | $0.5098 | $0.539 | $0.4881 | 1,159,205 | 07-10-2024 |
$0.4725 | $0.4175 | $0.4725 | $0.4799 | $0.41489 | 1,086,968 | 07-09-2024 |
$0.412 | $0.4116 | $0.412 | $0.4313 | $0.3789 | 587,432 | 07-08-2024 |
$0.4041 | $0.4301 | $0.4041 | $0.439 | $0.3697 | 656,560 | 07-05-2024 |
$0.4225 | $0.405 | $0.4225 | $0.4402 | $0.405 | 923,779 | 07-04-2024 |
$0.4225 | $0.405 | $0.4225 | $0.4402 | $0.405 | 923,779 | 07-03-2024 |
News, Short Squeeze, Breakout and More Instantly...
Aligos Therapeutics Inc. Company Name:
ALGS Stock Symbol:
NASDAQ Market:
Aligos Therapeutics Inc. Website:
Amoytop to sponsor a Phase 1b exploratory clinical study evaluating the efficacy and safety of ALG-000184 in combination with PEGBING® (Mipeginterferon alfa-2b) in CHB patients SOUTH SAN FRANCISCO, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, ...
Key Opinion Leader (KOL) event with Dr. Mark Sulkowski to discuss his perspectives on the chronic suppression regulatory pathway and future development plans following positive feedback from the FDA to move forward with chronic HBV DNA suppression as the primary efficacy endpoint Schedu...
2024-07-09 10:10:00 ET July 9, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Tech, Biotech, Cleantech and Mining Sectors. The newest tech company is involved in AI and Blo...